At the end of June, private equity firm Altaris, LLC announced its plans to acquire Sharecare, a digital health company, for $518M. Sharecare has an app that allows patients to store their health information, such as lab results and medications. The app also allows users to track their steps, vital signs, sleep data, and health insurance information. The deal is expected to close in the last half of 2024. Following the acquisition, Altaris plans to take Sharecare private.
Other health tech startups, such as Function Health, are gaining significant attention within the industry. For a $499 annual membership, Function Health offers consumers access to over 100 lab tests including hormones, thyroid, immunity, and cancer signals. Impressively, the platform now has 50,000 users and a waitlist of over 200,000 people. To date, the company has raised $53M, with backing from celebrities such as Kevin Hart and Matt Damon.
Across digital health startups, funding is steadily increasing. According to a report published by Rock Health, digital health startups raised a total of $5.7B in the first half of 2024, with a trajectory to surpass 2023 funding.
Our three things that matter:
1. There is renewed investor interest in digital health startups. This surge is largely driven by interest in Artificial Intelligence (AI). According to the Rock Health report, one in three investment dollars went to companies utilizing AI in the first half of the year.
2. Private equity firms are increasingly acquiring digital health startups, with ten acquisitions in the first half of 2024 compared to nine total in 2023. The reason for this occurrence is twofold: private equity firms view opportunities for rapid growth—especially with innovative tools such as AI—while larger digital health companies remain conservative in their acquisitions. Notably, acquisitions by
larger digital health companies are more than halved so far this year compared to the same period last year.
3. The digital health market is strengthening as evidenced by the return of public exits and a focus on early-stage deals. After nearly two years without any initial public offerings (IPOs), several companies—including Nuvo, Tempus AI, and Waystar—emerged on the New York Stock Exchange or Nasdaq. Further, 84% of deals were comprised of seed, Series A, or Series B funding. The amalgamation of these trends signals a strong pipeline of innovation and new entrants in the digital health space.
As private equity firms increase their acquisitions in digital health startups, how will their strategies compare to those of larger digital health companies? How will the rise of innovative tools like AI continue to reshape the investment landscape?
#ro3llc #Healthcare #DigitalHealth #PrivateEquity #MergersandAcquisitions #Startups